Divestiture strategy on track Portfolio includes prescription products in Takeda’s Cardiovascular/Metabolic and Anti-inflammatory therapeutic areas along with Calcium Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that it has entered into an agreement to divest a portfolio of select non-core prescription pharmaceutical products sold predominantly in Europe and Canada to Cheplapharm. Cheplapharm is a specialty pharmaceutical company headquartered in Germany with a 25-year history of successfully acquiring, integrating and growing pharmaceutical products. Takeda will receive an upfront payment of approximately $562 million USD, subject to customary legal and regulatory closing conditions. The portfolio to be divested to Cheplapharm is comprised of non-core prescription pharmaceutical products in a variety of therapeutic categories sold predominantly in Europe and Canada. This includes Cardiovascular/Metabolic and Anti-Inflammatory products along with Calcium. The portfolio generated FY 2019 net sales of approximately $260 million USD. While the products included in the sale address key patient needs in these countries, they are outside of Takeda’s five key business areas. With a more focused portfolio, the divestiture further enables Takeda’s Europe & Canada Business Unit (EUCAN) to focus on and drive strategic core growth areas. In April 2020, Takeda announced to divest EUCAN’s non-core over-the-counter (OTC) products to Orifarm Group. Giles Platford, President, EUCAN, Takeda, said, "These divestments represent another important milestone in our portfolio simplification and optimization strategy as we position Takeda for continued success across our five key business areas: Gastroenterology (GI), Rare Diseases, Plasma-Derived Therapies, Oncology and Neuroscience. We are pleased to have found a partner in Cheplapharm who shares our commitment to patient care and has the experience and resources to continue investing in these important products well into the future for the benefit of patients." Costa Saroukos, Chief Financial Officer, Takeda, said, "Today’s announcement allows Takeda to continue to be patient-focused as we streamline and optimize our portfolio according to our global long-term strategy. While the trusted products included in the sale address key patient needs in these countries, they are outside of our core business areas of focus. We are confident that Cheplapharm is the right partner to ensure patients continue to have access to these products." The sale of these non-core prescription products supports Takeda’s continued divestiture program. Last month, Takeda announced an agreement to divest Takeda Consumer Healthcare Company Limited to Blackstone for approximately $2.3 billion USD. In June, Takeda agreed to divest a portfolio of non-core assets sold exclusively in the Asia Pacific region to Celltrion for up to $278 million USD; in April, Takeda announced the sale of non-core OTC products in Europe to Orifarm Group for up to approximately $670 million USD, including the sale of two manufacturing sites in Denmark and Poland; and in March, Takeda announced the sale of non-core products in Latin America to Hypera Pharma for $825 million USD, as well as completed the previously announced sales of non-core assets spanning the Russia-CIS region to STADA and in countries spanning the Near East, Middle East and Africa region to Acino. Transaction Details There are no anticipated employee transfers in connection with this transaction. The transaction is expected to close by the end of Fiscal Year 2020 (ending March 2021), subject to the satisfaction of customary closing conditions and receipt of required regulatory clearances. Until then, the products will continue to be made available to patients and manufactured and supplied by Takeda. Takeda intends to use the proceeds from this transaction to reduce its debt and accelerate de-leveraging toward its target of 2x net debt/adjusted EBITDA within Fiscal Year 2021 to 2023. Takeda is committed to rapid deleveraging driven by strong cash flow and divestiture proceeds, while also simplifying our portfolio. Takeda is being advised by J.P. Morgan as our financial advisor and White & Case is our legal advisor in this transaction. About Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries.
60k delayed buy from Friday declared late yesterday. News coming perhaps?
LOOKS LIKE A 3 YEAR HIGH ? 1 FOR 10 CONSOLIDATION 16TH SEPTEMBER 2020 ( Wi )
Welcome to the new Integumen live discussion forum! Messages posted in the Integumen live discussion will be logged here for posterity.
Time to buy in again here. Satoshipay look to have got its act together at last and deliver on B2B payments. Esports investments are doing really well in addition to that.
CHART SHOWS ON 22/09/18 THEY WERE ABOUT 0.45p SHOWS A HUGE SPIKE 27 DEC 2019 TO 3.35p ( must be mistake as around consolidation time ) BIG FALL STARTED ABOUT MARKET LOW TIMES 12 MARCH 2020 FROM 2.48p TO 0.78p THAT BEING THE BOTTOM 14 APRIL NOW 1.11p
YES HOPEFULLY THE ( D ) BUY ONLY ON 17/09/2018 .. THEY CONSOLIDATED AT ONE FOR ONE HUNDRED 24/12/2019 AND NAME CHANGED. DOWN ABOUT 90% @ 1.2p
This seems to be the new name for Regency mines
Shares in FastJet (FJET) have today left the AIM casino so are now untradeable, as well as essentially worthless. Remaining investors face mega dilution or administration or most possibly both. Having warned folks extensively over the years about an operation first set up to smuggle tobacco and which just could not turn a legitimate cent, I feel somewhat vindicated. But there is more… Citigate Dewe Rogerson and the half to £1 million of shareholders cash spunked on nothing!